A Phase 3 Randomized Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-Paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Unresectable Pancreatic Cancer
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC) 2) Locally advanced and unresectable pancreatic cancer

You may not be eligible for this study if the following are true:

  • 1) Prior chemotherapy or radiation for pancreatic cancer 2) Previous (within the past 3 years) or concurrent malignancy diagnosis except non-melanoma skin cancer and in situ carcinomas (excluding in-situ breast cancer) 3) No major surgery for 4 weeks prior to signing consent form. Biliary stents are permitted


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.